肥胖不影响并发症和转换到膝盖全关节整形术后高骨切除术:一个系统的审查
Chandler Harris1, Fahad Nadeem1, Mathew Hargreaves2
1University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.
概括
肥胖不会对高骨切除 (HTO) 后的结果产生负面影响. 与接受HTO的非肥胖个体相比,肥胖患者的症状缓解和并发症率相似.
科学领域:
- 整形外科手术 整形外科手术
- 生物医学工程 生物医学工程
- 重建性手术是一种重建性手术.
背景情况:
- 高骨切除术 (HTO) 是一种手术程序,用于纠正下肢不对齐.
- 肥胖症是骨科患者群体日益关注的问题.
- 肥胖对HTO结果的影响需要进一步澄清.
结论:
- 高骨切除术是肥胖患者的一种可行的选择,这些患者患有单部位膝盖磨损和冠状元不对齐.
- 肥胖似乎不会增加并发症风险或恶化HTO后的功能结果.
- 外科医生可以对符合条件的肥胖患者有信心考虑HTO.
更多相关视频
05:30Surgical Approach and Complications of Stand-alone Lateral Trans-Psoas Interbody Fusion
Published on: February 14, 2025
782
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
224
相关概念视频
Drug Dosing: Obese Patients
368
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
368
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
440
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
324
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
324
